Wexford Capital’s TG Therapeutics TGTX Stock Holding History

Wexford Capital’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12,000	Closed	-$432K	–	453
2025 Q2	$432K	Buy	12,000 +2,000	+20%	+$74.5K	0.12%	115
2025 Q1	$394K	Sell	10,000 -4,000	-29%	-$135K	0.1%	133
2024 Q4	$421K	Buy	+14,000	New	+$402K	0.07%	113
2013 Q4	–	Sell	-30,000	Closed	-$151K	–	267
2013 Q3	$151K	Sell	30,000 -10,000	-25%	-$61.2K	0.01%	193
2013 Q2	$256K	Buy	+40,000	New	+$256K	0.02%	160

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wexford Capital's TGTX Position: Q3 2025 in Review

Wexford Capital sold out of TG Therapeutics (TGTX) in Q3 2025, closing a stake of 12,000 shares — an estimated $432K sold.

Wexford Capital first reported a position in TGTX in Q2 2013 and held it in 5 quarters. The position peaked at $432K in Q2 2025. 354 funds tracked by Wall St. Rank hold TGTX as of Q3 2025.

Wexford Capital reported no remaining TG Therapeutics position as of Q3 2025 after selling out during the quarter.
Wexford Capital sold 12,000 TG Therapeutics shares in Q3 2025, an estimated $432K.
Wexford Capital first reported a position in TG Therapeutics in Q2 2013 and held it in 5 quarters.
Wexford Capital's TG Therapeutics position peaked at $432K in Q2 2025.
354 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2025.

Based on Wexford Capital's 13F filing for Q3 2025, filed 14 Nov 2025.